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Abstract
This chapter aims to explain the functional impact of the proteasome activator (PA)28γ
protein in cellular survival. The mechanistic complexity of this proteasome activator,
encoded by the PSME3 gene and overexpressed in tumors in correlation with the degree
of severity, is attracting growing attention. Taking anti-apoptotic properties of PA28γ into
account, a simple view might explain therapy resistance of tumors by the presence of high
concentrations of this proteasome regulator. A more sophisticated approach would con-
sider functional parameters such as subcellular distribution, competition with other
proteasome regulators, and factors affecting heptamer assembly, proteasome binding,
and activation. Recently, PA28γ has been attributed as a proteasomal recognin, particu-
larly for intrinsically unstructured proteins (IUPs), targeted by ubiquitin-independent
proteasomal protein (UIPP) degradation. Other reports demonstrated inhibitory or stim-
ulatory effects of PA28γ on turnover of substrates of the ubiquitin- and ATP-dependent
proteasome system (UPS). Since the understanding of functional implications of PA28γ on
diverse signaling processes has grown exponentially and the orchestration of proteolytic
systems within apoptosis is fairly complex, this article summarizes the recent develop-
ments in PA28γ biology with emphasis on cell survival signaling pathways such as DNA
repair and apoptosis.
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double-strand break (DSB), DNA damage response (DDR), B-cell lymphoma-extra-large
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1. Introduction
Posttranslational modification and regulated intracellular proteolysis are intimately linked with
regulation of proliferation, differentiation, and apoptosis. Aforementioned survival processes
depend on the steady-state levels of proteins acting as molecular switches of signaling networks
and regulated proteolytic systems activating or removing such switches. Proteasomal protein
degradation bifurcates into ubiquitin-dependent pathways, namely, the ubiquitin proteasome
system (UPS) and ubiquitin-independent proteasomal protein (UIPP) degradation pathways [1].
Due to the modular structure of the proteasomal proteolytic system, composed of 20S proteas-
omes, 19S regulatory particles (RP), and 11S proteasome activator 28 (PA28) subtypes, it is
challenging to identify definite relations between 20S proteasomes, regulator-associated protea-
somes, and their substrates.
Among 11S regulators, proteasome activator 28γ (PA28γ) has earned remarkable attention,
due to its pronounced overexpression in cancer and its functional relation to tumor biology.
Several evidences indicate that PA28γ, in addition to its role as a 20S proteasome activator and
as a putative substrate recognition module, might also act as a modulator of E3 ubiquitin
ligases. Since the first contributions of PA28γ to UIPP have been reviewed a decade ago [2], a
reevaluation of proteasome biology with a focus on the intrinsic pathway of apoptosis seems
justified. Growing knowledge about the remarkable efforts of various proteasomal proteolytic
systems in cell survival will improve the mechanistic knowledge for target definition and
specific drug design to counterstrike cancer [3].
2. Ubiquitin proteasome system (UPS)
The discovery of the ubiquitin proteasome system seems to be a never ending story of surprise,
starting with the first observations of non-lysosomal, ATP-dependent protein degradation [4],
recognizing ubiquitin as a barcode label for proteins dedicated for proteasomal degradation [5]
and, finally, realizing that ubiquitin labeling is not an absolute requirement for proteasomal
recognition, unfolding, and decay [6].
2.1. Ubiquitin conjugation and barcode properties
The enzymatic machinery-conjugating ubiquitin (Ub) or ubiquitin-like proteins (UBLs) to
lysine is based on hundreds of enzymes, activators, inhibitors, and substrate adaptors,
establishing an information-based system for multiple purposes in signal transduction. Fifteen
human E1 enzymes (ubiquitin-activating enzymes (UBAs)) initiate the conjugation cascade
either specifically using ubiquitin or one of the ten different UBLs as substrate. Thioester-
linked E1-Ub/UBL can be transferred to about 80 E2 enzymes (ubiquitin-conjugating UBC)
via transesterification to the thiol group of an active site cysteine. Finally, more than 600
monomeric or multimeric E3 enzymes (ubiquitin protein ligases), either harboring RING or
HECT domain motifs, constitute molecular scaffolds catalyzing the substrate-specific transfer
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of thioester-linked Ub/UBL mostly to lysine residues of substrate proteins. Since ubiquitin
contains seven putative conjugation sites, linear or branched Ub conjugates can be formed by
isopeptide bonds creating individual barcodes. Processing of conjugates, either as a require-
ment for substrate channeling into proteasomes or for fine tuning the barcode information, is
performed by cysteine proteases of the deubiquitinase (DUB) protein family [7]. The resulting
barcodes are guiding proteins into different fate decisions, namely, affecting subcellular loca-
tions (UBL:SUMO), enzymatic activity (UBL:NEDD8), or 26S/30S proteasomal turnover (UBL:
ubiquitin) [3–5, 8].
Ubiquitin-K48 conjugates are mostly used as degradation signal [5] that can be recognized by
19S regulatory particles (PA700) attached to one or both ends of 20S proteasomes, either
forming 26S or 30S proteasomes, respectively [9].
2.2. 20S proteasomes
2.2.1. Core proteases of UIPP and UPS
The term “20S proteasome” encompasses variant isoforms of compartmentalized, barrel
shaped 700 kDa core proteases (CP) of α1–7β1–7β1–7α1–7 stoichiometry [10]. Six active site
β-subunits of the catalytic chamber are processed from zymogenic β1, β2, and β5 precursor
subunits during standard (s20S) proteasome assembly, establishing the amino-(N)-terminal
threonine nucleophiles central to the catalytic mechanism [11]. Proteasomes reveal cleavage
site preferences for hydrophobic, basic, and acidic P1 residues resembling specificities of
prototypic proteases (chymotrypsin-like (CHYT), trypsin-like (TRYP), caspase-like (CASP).
Typically, for a compartmentalized protease, access to the active sites is regulated by gated
pores, formed by the amino-terminal chains of α-ring subunits [12]. The narrow orifice formed
by the α-rings restricts access of most native proteins. Therefore, unstructured protein regions
or protein unfolding is a prerequisite for substrate channeling, conducted by 19S 11S
proteasome activators [12–15].
Due to tissue-specific or cytokine-inducible expression of proteasomal active site subunits [16,
17], a high diversity of 20S proteasome complexes is principally available to associate with
proteasome activators (PA) such as PA700 (19S), PA28αβ, or PA28γ (11S). As reviewed else-
where [9, 10], proteasomes have been purified and biochemically characterized from various
sources, most recently discovering the unique properties of 20S proteasomes from thymus
(t20S) [18], a discovery highly relevant for the understanding of positive selection of T cells
[19]. Constitutively, expressed standard 20S proteasomes (s20S) and immune proteasomes
(i20S) have been compared with respect to their different assembly kinetics, half-lives, and
catalytic capabilities [20].
The pro-inflammatory cytokine interferon-γ (IFN-γ) modulates the composition of the
immunoproteasome (i20S), due to the expression of zymogens (pro-subunits) of inducible
active site subunits (iβ1, iβ2, iβ5). During POMP-dependent proteasome assembly in proxim-
ity to the ER, active site subunits of constitutively expressed proteasomes (s20S) are replaced
by the inducible subunits, forming immunoproteasomes (i20S). The i20S complexes reveal
faster assembly (about 21 versus 80 min) and shorter half-lives (27 versus 133 h) and differ in
Proteasome Activator 28γ: Impact on Survival Signaling and Apoptosis
http://dx.doi.org/10.5772/intechopen.74731
73
activity and cleavage site preferences from s20S proteasomes [21, 22]. In concert with other
intracellular proteases, combinations of both 20S isoforms, associated with 11S/19S activator
complexes, contribute uniquely to processing of peptides for MHC class I antigen presentation
of self or foreign antigens [23].
2.3. 19S regulatory particle and 26S/30S proteasomes
Degradation of ub-labeled proteasome substrates depends on 26S/30S proteasomes. These
protease complexes contain either one or two 19S regulatory particles (RP) associated with
the α-ring subunits of s20S or i20S CPs. The 19S RP (proteasome activator PA700) is com-
posed of base and lid sub-complexes that reveal defined pathways of chaperone-assisted
assembly [9]. The base ATPase sub-complex (subunits Rpt1–Rpt6) harbors a chaperon-like
unfoldase activity [24] and is involved in substrate channeling into 26S or 30S proteasomes.
The lid sub-complex enables ub-conjugate binding, as well as deubiquitination for ubiquitin
recycling and substrate channeling. Assembly, composition, and topology, as well as specific
biological aspects of 26S/30S proteasome genesis and function, have been reviewed compre-
hensively by others [20, 25, 26].
2.4. Proteasome activator 28αβ and MHC class I antigen presentation
The proteasome activator (PA) 28 protein family is encoded by three PSME genes. The IFNγ-
inducible PSME1 and PSME2 genes accompany immunoproteasome expression. However,
preferential association with i20S versus s20S proteasomes has not been supported by in vitro
kinetics of proteasome activation [14]. Apart from their ability to form homo-heptameric
proteasome-activating complexes in vitro, the PA28α and PA28β subunits prefer assembly
into PA28α4β3 hetero-heptamers as revealed by kinetic and structural analysis [14, 15].
PA28α4β3 activates 20S proteasomes by channeling, regulating the width of the narrow orifice,
and excluding natively folded protein substrates. The control of substrate import and export of
peptide products, possibly as a molecular sieve, or due to allosteric regulation of proteasomes
by PA28α4β3 may affect proteasomal processivity and quality of peptide products [27, 28].
Double knockouts of the IFNγ-inducible members of the PSME1 and PSME2 genes [29] were
examined with respect to immunological functions and immunoproteasome assembly. Sub-
stantiating the role of so-called hybrid proteasomes (PA28α4β3-20S proteasomes) [30, 31], it
was found that association of 26S proteasomes with PA28α4β3 increased proteasomal activity
and presentation of particular antigens [29]. However, PA28αβγ-null mice showed normal
antigen presentation with some antigens and impairment with others. Based on these obser-
vations, it has been stated that PA28αβγ is not a prerequisite for antigen processing in general,
but seems to be essential for the processing of certain CTL epitopes [23].
2.5. Biochemical properties of proteasome activators 28γ
The third member of the PA28 protein family, proteasome activator (PA)28γ, encoded by the
PSME3 gene, was discovered as nuclear Ki autoantigen about four decades ago [32]. Biochem-
ical key features of the heptameric 11S regulator PA28γ [33–39] are summarized in Table 1.
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Particularly, roles in nuclear dynamics [40, 41], posttranslational modification [43–45], or contr-
ibutions in apoptotic signaling are emphasized [46, 47].
Application of PA28γ as a diagnostic marker in inflammatory autoimmune or neoplastic
diseases has been proposed [48, 49]. Initially identified as a nuclear autoantigen [32, 39, 50],
Table 1. Cellular biochemistry of PA28γ.
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context-dependent cytosolic presence has also been reported. In breast cancer, PA28γ accumu-
lates in nuclei, whereas in pancreatic cancer cells, PA28γ emerges in the cytosol [51], indicating
that cellular context generates diverse scenarios with respect to subcellular localization and
function of PA28γ. Nuclear-cytosolic shuttling, mediated by posttranslational modification,
depends on cell types and conditions [44, 52, 53]. Sumoylation of amino-terminal lysine
residues K6/14/12 by PIAS1 (E3) enhances cytosolic localization and increases stability, pre-
sumably prerequisites for proteasome association and substrate recognition [44]. Contrarily,
acetylation at K195 by CREB-binding protein (CBP) favors assembly of nuclear PA28γ.
Deacetylation by sirtuin 1 (SirT1) has been demonstrated in mammalian cells. Since K6 and
K14 residues can be acetylated as well, competition with sumoylation cannot be excluded [45].
Furthermore, phosphorylation of PA28γ by protein kinase MEKK3 resulted in a concomitant
increase of PA28γ levels in Cos cells [43]. Stress kinases Chk2 and ATM have been reported to
phosphorylate PA28γ, thereby affecting protein-protein interactions (PPI) and functions in
DNA damage response [42].
2.6. Overexpression of PA28γ in cancer
Several authors showed the association of PA28γ with tumorigenic pathways and correlation
of expression with malignancy and metastasis. In skin carcinogenesis, PA28γ is involved in
modulating WNT signaling [54]. The improved survival properties of PA28γ overexpressing
cells [46] and the well-documented overexpression in tumors and cancer cell lines raise the
question, how PSME3 gene expression is regulated on the transcriptional and translational
level.
PA28γ-mediated mechanisms supporting cell survival in cancer cells are of high relevance for
cancer therapy, particularly in the light of profoundly increased levels of PA28γ in cancer cell
lines and in tumor tissue. Highly increased steady-state level of PA28γ was observed majorly
in epithelial and mesenchymal tumors such as thyroid neoplasm [55]; breast tumors, particu-
larly those with poor prognosis [56–58]; colorectal cancers [48]; hepatocellular carcinoma [59];
and oral squamous cell carcinoma (OSCC) [60].
3. The PA28γ scaffolding hub in tumor biology
A particular interest of this article is the question, how UPS and UIPP are involved in regulat-
ing cell survival pathways intimately linked with tumor biology and therapy resistance
(Figure 1). Cyclin-dependent protein kinases (CDKs) are one regulatory implement of prolif-
erative control. As indicated in Figure 1A, the PA28γ-dependent degradation of several CDK
inhibitors (CDKIs) has been observed [61]. Surprisingly, expression of thermo-labile E1
enzymes in ts20TG or tsBN75 cells did not impair degradation of p21 [62]. Furthermore,
contribution of SCF E3 ligases in p21 degradation could be excluded, since ts41 cells harboring
a temperature sensitive mutation in the NEDD8-activating enzyme did not reveal an increased
p21 half-life at the restrictive temperature. However, p21Cip1 half-life, and similarly that of
lysine-less p16INK4A or p19Arf, was extended in embryonic fibroblasts from PA28γ knockout
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mice [61]. Noteworthy, aforementioned CDKIs had measurable slow rates of proteasome-
dependent turnover after depletion of PA28γ, indicating that PA28γ-20S proteasome UIPP is
more efficient than the PA28γ-independent pathway. Furthermore, inhibition of amino-
terminal ubiquitination via acetylation or mutagenesis of internal lysine residues did not
impair degradation of p21 [62]. Degradation of the three mentioned CDKIs could be
performed by 20S proteasomes, but not by 30S proteasomes in vitro [61].
PA28γ-mediated effects can be assignedmechanistically to distinct categories (Figure 1). Firstly,
central to its role in UIPP, PA28γ recruits substrates for degradation by the 20S proteasome.
CDKIs revealing features of intrinsically unstructured proteins (IUP) are prototypic for this
mode [61].
Secondly, a cross talk between UIPP and UPS is established, since 11S and 19S regulators
compete for binding to 20S proteasomes. Interestingly, overexpression of PA28γ correlates
with the increase of some UPS substrates such as c-Myc [63], ERα [58], BclXL, or MART-1
[46]. Such stabilization may indicate inhibitory effects on specific E3 enzymes, UIPP degrada-
tion of auxiliary UPS factors, or reduction of the active 30S proteasome pool. Perhaps, putative
30S substrates may escape UPS degradation due to activation of DUBs. Thirdly, UPS-mediated
degradation might be affected either by degradation of specific E3 enzymes (Smurf1; [64, 65])
or by enhancing the interaction of specific E3s with their substrates, as has recently been
shown for Mdm2:p53:PA28γ [66].
Here, PA28γ promotes the interaction of p53 and Mdm2 (Figure 1B), thereby reducing total p53
levels in UV-C-radiated cells via the ubiquitin-dependent proteasomal degradation pathway.
Figure 1. Mechanistic diversity of PA28γ-mediated protein turnover. (A) Typical protease complexes and substrates of
UIPP. (B) Core components of UPS. Note, that UIPP and UPS are connected by cross talk: 11S and 19S regulators compete
for binding to the 20S core protease. Increased assembly of PA28γ complexes is supposed to reduce the relative amount of
30S proteasomes. In cells overexpressing PA28γ, certain proteasomal substrates of PA28γ-20S proteasomes may be
recognized by increased turnover, while others may accumulate due to UPS inhibition. The second mode of cross talk
takes place, if UIPP degrades E3 enzymes or components required for their activation. As the third mode, PA28γ might
increase PPI between E3s (Mdm2) and their substrates (S1, p53), thereby increasing UPS-dependent substrate turnover.
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Silencing of the PSME3 gene, as well as application of Nutlin-3, an inhibitor of Mdm2:p53
interaction, resulted in exaggerated stabilization of p53 in HCT116 or A549 cells, respectively [66].
In general, proteasomal contribution to degradation of regulatory proteins has been confirmed
by using proteasome inhibitors in an adequate concentration range, thereby stabilizing either
the protein of interest (POI) or its ubiquitin conjugates. Ubiquitin conjugates of specific POIs
have been demonstrated after transient expression of HA-tagged ubiquitin, HA-pulldown
techniques, and consecutive immunoblot analysis. Cellular systems with thermosensitive E1
enzymes were used to demonstrate dispensability of ATP-dependent ubiquitination for some
proteasomal substrates. Depletion of subunits crucial for 19S assembly by siRNA silencing and
in vitro degradation assays based on purified proteasome complexes either with or without
regulators are alternative approaches to demonstrate UIPP or UPS involvement [1].
3.1. PA28γ in DNA damage response
DNA double-strand breaks (DSBs) may lead to chromosomal rearrangements, dysfunctional
gene expression, or even aneuploidy, if not properly being targeted by the DNA damage
response (DDR). The DDR is a tightly regulated nuclear process, organized majorly by post-
translational modification (PTM) signals, implemented by certain stress protein kinases. It has
been presumed that DSB mobility and nuclear chromatin dynamics may serve to support
DNA repair in nuclear sub-compartments [67]. Major DNA repair pathways are carried out
within a highly organized three-dimensional nuclear environment. Homologous recombination
(HR) occurs throughout the cell cycle, while nonhomologous end joining (NHEJ) is restricted
to S and G2 phases.
Recently, ATM- and PA28γ-dependent recruitment of 20S proteasomes to sites of DSB has been
demonstrated by live cell imaging [42]. PA28γ depletion enhanced the focal retention of pro-
teins of the DNA repair machinery (MDC1, 53BP1, RNF8, or BRCA1) at DNA damage sites,
whereas early accumulation of focal proteins and initial formation of modified histone γH2AX
were not affected. PA28γ silencing moderately reduced the NHEJ pathway, whereas the HR
pathway was markedly enhanced. PA28γ seems to assemble proteasomes at the sites of DSB
during early stages of the DNA repair pathway [42].
3.2. PA28γ in nuclear dynamics
While varying levels of chromatin compaction result in euchromatin and heterochromatin,
nuclear bodies structure interchromatin as well [68]. PA28γ and 20S proteasomes have been
found to be physically associated with nuclear structures such as nuclear speckles [40], Cajal
bodies (CBs) [41], and PML bodies [69, 70] or have been associated with nuclear survival
functions and chromosomal stability [71].
Nuclear speckles as subnuclear interchromatin domains are enriched in components of the
pre-mRNA splicing machinery. 20S proteasomes and PA28γ co-localize in such NS structures
[40]. PSME3 silencing affects NS organization and recruitment of splicing factors of the SR
family to transcription sites. Proteasome inhibitors promote the accumulation of SC35 in NS.
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Contributions of UIPP and/or UPS to NS protein dynamics seem to be crucial for nuclear
speckle function.
CBs are sites of assembly of small nuclear ribonucleoproteins and small noncoding RNA traffic
[72]. They are specific nuclear targets of the cellular stress response [41]. It has been shown that
UV-C irradiation induces a stable association of PA28γ with coilin, the intrinsically disordered
marker protein of CBs. The accumulation of PA28γ correlates with the disruption of CBs.
Apart from its canonical targeting via Mdm2, the unstructured nature of coilin and its associ-
ation with PA28γ might be the first evidence for coilin targeting via UIPP.
3.3. PA28γ in infection and inflammation
PA28γ and NF-κB signaling constitute activation loops affecting inflammatory processes [73]
and bacterial infection [74]. Since inflammatory states are preceding neoplastic transformation,
the molecular link between PA28γ and NF-κB biology might be of relevance in tumor biology.
The PSME3 gene is under control of the transcription factor NF-κB. Since inhibitory proteins of
NF-κB signaling are substrates of a PA28γ-mediated UIPP, NF-κB-mediated transcription
depends on PSME3 expression and vice versa. This positive feedback regulation between
PSME3 gene regulation and NF-κB-directed transcriptional regulation has been observed in
two different models. First, IκBε degradation prevents the removal of NF-κB from sites of
transcription, promoting constitutive activation of inflammatory pathways in the gastrointes-
tinal mucosa. A DSS colitis model demonstrated the requirement of PA28γ for the pathological
process. PSME3 knockout resulted in impairment of the DSS colitis pathology [74]. The second
target of PA28γ in NF-κB signaling is KLF4, a negative regulator of NF-κB. Targeting of KFL4
by the PA28γ-proteasome releases the negative modulatory effect on NF-κB, resulting in a
higher PSME3 expression and further activation of the inflammatory response to counterstrike
bacterial infection [73].
Accessing sera of autoimmune and cancer patients, we observed an increased level of extracel-
lularly localized PA28γ in patients suffering from a diverse spectrum of autoimmune diseases.
In patients with rheumatoid arthritis, the level correlated with the disease state and responded
to treatment with abatacept [49]. Since PA28γ has been associated with sepsis [75] or wound
healing [76], development of clinical applications beyond autoimmune or cancer diagnosis is
an emerging future perspective.
3.4. Transcriptional regulation of metabolism
Transcription factor c-Myc, a highly unstable protein [63, 77, 78], acts as a heterodimer with
Max, recruiting coactivators through CACGTG-binding motifs to promotors of target genes
involved in the regulation of cell growth, proliferation, metabolism, and apoptosis. Interestingly,
c-Myc appears to be targeted by diverse PTMs and proteolytic mechanisms. UPS-dependent
degradation of c-Myc depends on several E3 enzymes, F-Box proteins, and antagonizing
pathways [79]. Using gene set enrichment analysis, PA28γ was shown to reprogram energy
metabolism via the c-Myc-glycolysis axis, affecting glucose utilization and lactate production
in cancer cells. PSME3 gene silencing reduced c-MYC levels, whereas the increased levels of
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PA28γ in cancer cells increased Myc. High levels of PA28γ protein in the cytosol and nucleus
repress UPS-mediated c-Myc decay and reprogram pancreatic tissue and pancreatic cancer cell
lines metabolically [80]. These results were surprising, since overexpression of PA28γ in Hela
cells promoted degradation of c-Myc, while depletion of PA28γ markedly increased the pro-
tein stability of c-Myc [51]. These contradictory observations indicate contextual variability of
c-Myc turnover in pancreatic tumors versus other models and underline the requirement for
studies focusing on cross regulation of UIPP and UPS.
3.5. PA28γ: Impact on autophagy and metabolism
Highly selective proteolytic systems such as UPS or UIPP, responsible for the selective
and regulated degradation of proteins, are supplemented by autophagosomes and ub-based
substrate labeling for cargo selection. Ubiquitin-like proteins and a corresponding conjugation
system are initially involved in phagophore formation, a process, which integrates phosphati-
dylethanolamine-linked LC3-II into both leaflets of the autophagosome. Cargo receptors for
ubiquitinated proteins such as p62 are recruited to autophagosomes via LIR domains (LC3-
interacting region (LIR)). Finally, degradation of bulky aggregates or organelles can be
conducted by lysosomal proteases during basal autophagy. Under environmental stress condi-
tions, as an adaptive survival strategy, autophagy can be gradually upregulated, avoiding
excessive activity of autophagy which may lead to cell death. The regulation of this sophisticated
machinery for bulk degradation has recently been reviewed [81]. Interestingly, since Bcl-2 family
proteins are closely linked to cytoprotective responses, regulation of metabolism, and apoptosis,
the involvement into regulation of autophagy is not surprising. Generally, anti-apoptotic mem-
bers such as BclXL can inhibit autophagy, whereas pro-apoptotic BH3-only proteins may
induce autophagy. The principal behind anti-apoptotic or anti-autophagic roles of BclXL may
be considered simply the same, while complexity in cross talk between autophagy and apo-
ptosis majorly results from BclXL phosphorylation and subcellular localization. BclXL has been
reported to be localized in the cytosol, the nuclear envelope, the endoplasmic reticulum, and
the outer mitochondrial membrane, establishing BclXL pools of different functionalities. In
anti-apoptotic signaling, BclXL antagonizes pro-apoptotic proteins via physically interacting
with Bax, cytochrome c, or cytosolic p53, preventing MOMP [82, 83]. Binding of Beclin 1 to
BclXL prevents assembly and activation of class III phosphatidylinositol 3-kinase (PI3K) com-
plex, which is involved in autophagosome function.
Similarly, multifaceted as pro-survival factor BclXL [82], anti-apoptotic PA28γ protein reveals a
plethora of PPIs and functional versatility. Targeting of deacetylase SirT1 for PA28γ-20S
proteasome-mediated UIPP degradation was shown to regulate liver autophagy [84]. Defi-
ciency of PA28γ as well as energy starvation dissociates the REGγ-SirT1 interaction and
releases SirT1 to deacetylate components of the autophagy machinery, thereby stimulating
autophagy.
Analyzing metabolic parameter of PA28γ knockout mice, a reduction of ATP consumption,
possibly due to an inhibition of rDNA transcription, has been demonstrated. Under starvation,
nucleolar deacetylase SirT7 was negatively regulated by PA28γ. Consistently, depletion of
PA28γ induced increased Sirt7 levels, as well as increased ATP consumption. These observations
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might be of relevance for cancer therapy, since PA28γ depletion sensitizes tumors to treatment
with hexokinase inhibitor 2-desoxy-glucose [85].
3.6. Cross talk of UIPP and UPS in the regulation of apoptosis
3.6.1. Stoichiometry of 20S proteasomes and regulators in cellular systems
The stoichiometry of the key regulators of UPS and UIPP, namely, 19S and 11S regulators, is of
particular interest to further understand how cross talk of these two proteolytic systems is
affected by PA28γ. Since each biochemical process is restricted kinetically by its rate limiting
step, the assembly of proteasomal complexes should be a matter of serious debate. Only few
studies so far covered this question due to methodological limitations. Therefore, a recent
proteomic approach is remarkable, elaborating the stoichiometry of 20S proteasome-associated
regulators in detail [86, 87]. Using formaldehyde cross-linking in combinations with 20S-
complex directed affinity purification on MCP21-coupled sepharose, and applying mass spec-
trometric quantification, proteomic analysis compared the stoichiometry of 20S proteasome
complexes in nine different cell lines. Interestingly, 19S and 20S particles reached 1:1 ratio, but
PA28γ-associated proteasomes occurred as minor species, occupying about 1–0.2% of
proteasomes [86]. All investigated cellular systems had in common that about 20–40% of 20S
proteasomes persisted in a regulator-unbound state, establishing a pool of proteasomes
directly available for UIPP tasks or for dynamic behavior in the case of expressional alterations
in the activator population [86].
As central pathways of protein degradation, UPS and UIPP participate in regulating the
delicate balance of pro- and anti-apoptotic proteins and cell cycle regulators [88, 89]. The
contribution of proteasomal degradation in controlling crucial steps of the mitochondrial
pathway of apoptosis has been reviewed comprehensively [89]. Here, we are focusing on the
PA28γ-mediated mechanisms, affecting the balance between pro- and anti-apoptotic regula-
tory proteins (Figure 2).
3.6.2. Discovery of anti-apoptotic properties of PA28γ
Initial studies on PA28γ-deficient mice suggested a role for PA28γ as a regulator of cell
proliferation and body growth [90]. Lack of PA28γ did not affect expression of other PSME
family members such as PA28α or PA28β and resulted in smaller body size. Entry into S phase
was impeded and number of G1 cells increased. MEFs depleted in PA28γ revealed increased
spontaneous apoptosis during logarithmic growth.
Recently, we demonstrated a correlation between cellular PA28γ levels and the sensitivity of
cells toward apoptosis in different cellular contexts, thereby confirming a role of proteasome
activator PA28γ as an anti-apoptotic regulator [46]. We investigated the anti-apoptotic role of
PA28γ upon UV-C stimulation in B8 mouse fibroblasts stably overexpressing the PA28γ-
encoding PSME3 gene and upon butyrate-induced apoptosis in human HT29 adenocarcinoma
cells with silenced PSME3 genes. Interestingly, our results demonstrate that PA28γ has a strong
influence on different apoptotic hallmarks, especially the levels of transcriptionally active
phosphorylated p53, BclXL, and active effector caspases (Figure 2) [46].
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3.6.3. Connecting the p53 activity status and PA28γ biology
The biology of p53, a key regulator of DDR and apoptosis, appeared recently being intimately
connected to PA28γ. Our data on UV-C-induced apoptosis in murine fibroblasts
overexpressing PA28γ revealed an increase of phosphorylated nuclear p53, paralleled by
cytosolic disappearance of p53. Kinetic experiments of apoptosis induction showed that pro-
tein levels of pro-apoptotic Bcl-2 family member Bax, cell cycle inhibitor p21, and ubiquitin E3
ligase MDM2 were transcriptionally upregulated in a time-dependent manner, indicating an
increased level of transcriptionally active p53 in a pro-apoptotic context.
Furthermore, it was observed in endometrial cancer that mutant p53R248Q promoted the upre-
gulation of the PSME3 gene [91]. That the PSME3 gene locus is under inhibitory transcriptional
control has been reported too. Wild-type p53 inhibits the PA28γ-20S UIPP pathway by
repressing PSME3 gene transcription, whereas mutant p53 was unable to repress PSME3
transcription [92].
Among other cellular survival functions, the p53 tumor suppressor protein particularly regu-
lates key decision points of DNA repair and apoptosis via affecting transcriptional regulation
of pivotal regulators of these two processes. Under normal conditions, the p53 protein is consti-
tutively degraded via Mdm2-mediated ubiquitination and the 30S proteasome (Figure 2D).
Under non-apoptotic conditions, PA28γ facilitates cytosolic redistribution of p53 by enhancing
its nuclear export via a mechanism involving mono-ubiquitination [53]. Cytosolic p53 can
activate MOMP via Bax, a mechanism prevented or balanced by the p53:BclXL and BAX: BclXL
interactions [82]. Similarly, a release of cytochrome c into the cytosol, triggering apoptosome
formation (Figure 2A), can be antagonized by Cyt c:BclXL [83] or p27:Cyt c interaction (p27,
small heat shock protein), while other heat shock proteins counteract via interaction with Apaf-1
(Figure 2A). One key regulator in this picture is BclXL, which responds transcriptionally to p53
activation and is posttranscriptionally downregulated by PARK2, the specific E3 ubiquitin ligase
preparing BclXL for UPS-mediated degradation (Figure 2B). Another anti-apoptotic regulator of
MOMP, Mcl-1, is similarly targeted for degradation by Mule E3 ubiquitin protein ligase
(Figure 2B) [82, 89].
DNA damage-induced ATM protein kinase (Figure 2D) activates p53 by phosphorylating p53
and Mdm2, thereby regulating Mdm2 oligomerization and processivity [93]. As a result of site-
specific phosphorylation (human p53 Ser15P or mouse p53Ser18P), p53 becomes stabilized and
translocates into the nucleus. Phosphorylated wild-type p53 tetramers are capable of promotor
and coactivator/corepressor binding [94].
In healthy cells, p53wt proteins cooperate with Smad3 in repressing the PMSE3 promotor [92].
Contrarily, tumor cells reveal high levels of p53mut activating the PMSE3 promotor via dere-
pression and/or activation with unknown coactivators. Consistently, elevated PA28γ levels have
been detected in several types of cancer and tumor cell lines [92]. These PA28γ-overexpressing
cells, hence, reveal higher resistance to apoptotic stimuli and increased proliferation.
In cancer cells, mutant p53 (p53mut) variants reveal alternative promotor selectivity. This might
explain how irreparable DNA damage in healthy cells results in transcriptional amplification
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of apoptosis due to increasing expression of pro-apoptotic genes, while in cancer cells an anti-
apoptotic scenario prevails.
3.6.4. Feedback regulation: PA28γ inhibits effector caspase activity
Overexpression of the PSME3 gene was accompanied by an increased resistance to apoptosis
induction. Even with elevated levels of BclXL and a partially impaired cytochrome c release in
PA28γ-overexpressing cells, we observed execution of the caspase-9/caspase-3 activation cascade
upon UV-C stimulation [46]. Surprisingly, PA28γ overexpression correlated with significantly
Figure 2. Impact of PA28γ on UIPP- and UPS-mediated regulation of apoptosis. (A) Mitochondrial regulation of apopto-
sis via MOMP, apoptosome assembly, and caspase activation. (B) Anti-apoptotic role of BclXL and its control via the UPS.
(C) Death receptor signaling and extrinsic activation of apoptosis via caspase-8 (CASP-8) depend on the intriguing UPS-
mediated regulation of the bid protein (reviewed by [89]). CASP-8 cleavage of bid generates amino- and carboxy-terminal
peptide fragments (N-tBid; t-bid-C) that act antagonistically. Anti-apoptotic N-tBid still bound to pro-apoptotic tBid-C
prevents apoptosis. Noncanonical ubiquitination at Gln and Cys residues initiates UPS-mediated degradation of N-bid.
N-bid degradation is required for activation of pro-apoptotic tBid-C. Inactivation of t-bid-C is realized by itch E3 ubiquitin
ligase, initiating its UPS-mediated degradation. This prevents mitochondrial outer membrane pore formation and activa-
tion of apoptosis. (D) Induction of stress kinases ATM and Chk2 by UV-C irradiation induces phosphorylation of p53,
Mdm2, and PA28γ, thereby disconnecting p53 from its constitutive restriction through E3 ubiquitin ligase Mdm2.
Phosphorylated nuclear p53 activates transcription of pro-apoptotic Bax, and cytosolic p53 can activate Bax-mediated
pore formation directly. It has been observed that PA28γ reduces p53 levels by enhancing Mdm2:p53 interaction [66]. (E)
Our model proposes a central role of anti-apoptotic PA28γ-20S UIPP in cancer cells [46]. High levels of PA28γ might be
based on altered promotor selectivity of mutant p53, which has been shown to increase PSME3 transcription, whereas
wild-type p53 represses PSME3 gene expression (D) [91, 92]. High PA28γ levels and acetylation are favoring heptamer
assembly and proteasome activation. UIPP, either based on 20S proteasomes alone or in association with PA28γ, may
reduce the level of released cytochrome c or activated caspases (CASP-9; CASP-3). If PA28γ levels are low, restriction of
caspases by UIPP is released, and monomeric PA28γ is targeted by effector caspases (CASP-3). Of note, experimental
evidences support the proteasomal degradation of effector caspases [46, 95], but the precise role of PA28γ in this process
remains to be investigated in detail.
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decreased active effector caspase levels. Consistently and vice versa, PMSE3 miRNA-mediated
PA28γ downregulation was accompanied by increased sensitivity to butyrate-triggered apo-
ptosis of HT-29 cells and increased levels of active caspase-3/caspase-7 [46]. Reduced caspase
activities were not due to transcriptional but posttranslational regulation.
The anti-apoptotic impact of high PA28γ levels could not solely be explained by enhanced
PA28γ-mediated degradation of pro-apoptotic p53 as suggested by others [66]. Our current
findings support a model (Figure 2A and E), where high PA28γ levels inhibit effector caspase-
3/caspase-7, while at low PA28γ levels, caspase-3/caspase-7 activity and PA28γ turnover are
increased. As a reasonable explanation, the high level of PA28γ favors heptamer stability,
whereas at low concentrations, monomeric PA28γ may be more susceptible to cleavage by
activated effector caspases [46, 47]. Furthermore, we found that proteasome inhibition stabi-
lized active caspase-3 levels, indicating that the PA28γ-dependent degradation of caspase-3/
caspase-7 is indeed proteasome-dependent [46]. Since the RING domain of IAP proteins
ubiquitinates caspase-3/caspase-7 [95], the canonical UPS is certainly involved in regulating
effector caspase activity. If PA28γ conducts restriction of caspase-3/caspase-7 activity through
enhancement of physical interaction between IAPs and caspases, or directly via the PA28γ-20S
proteasome UIPP route, has to be clarified in the future.
4. Concluding remarks
In light of the fact that the apoptotic potential of the cell is finally restricted by caspase levels
and their execution efficiencies [96], the importance of check and balance for controlling
caspase activity appears to be obvious. Recently, the impact of posttranslational modification
on activity and stability of caspase-3 has been reviewed [97]. Apart from inhibitory and
stimulatory phosphorylation, ubiquitination plays an important yet not a fully understood
role. However, cIAP1-dependent ubiquitination of a processing intermediate of caspase-3 was
followed by proteasome-dependent degradation of caspase-3. Interestingly, proteasome inhibi-
tors stabilizing majorly active caspase-3 among other effector caspases enhanced apoptosis [97].
The integration of the recent knowledge on proteasomal contribution to regulation of apopto-
sis via UIPP and UPS might lead to a refined concept in system biology of apoptosis [98].
Despite of the remaining questions, experimental evidences indicate that tumor survival and
resistance to therapeutic approaches may crucially relate to a plethora of new roles of PA28γ in
the regulation of apoptosis, autophagy, inflammation, and metabolic adaptation.
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